Subinay Ganguly

USPTO Granted Patents = 10 (Patent Applications = 7)

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 5.7

ph-index = 6

Forward Citations = 229(Granted Patents)

Company Filing History:

7 out of 3,699

Bristol-Myers Squibb Compnay

patents

3 out of 416

Janssen Biotech, Inc.

patents

Years Active: 2005-2024

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12180271 - Manufacturing methods for producing anti-TNF antibody compositions (2024-12-31),

2. 12129292 - Anti-tumor necrosis factor (TNF) antibodies and compositions thereof (2024-10-29),

3. 12122825 - Nucleic acid molecule encoding, and method of producing, a recombinant anti-tumor necrosis factor (TNF) antibody (2024-10-22),

4. 9382328 - Fully human antibodies against human 4-1BB (2016-07-05),

5. 8716452 - Fully human antibodies against human 4-1BB (2014-05-06),

6. 8137667 - Fully human antibodies against human 4-1BB (2012-03-20),

7. 7659384 - Polynucleotides encoding fully human antibodies against human 4-1BB (2010-02-09),

8. 7288638 - Fully human antibodies against human 4-1BB (2007-10-30),

9. 7214493 - Polynucleotides encoding humanized antibodies against human 4-1BB (2007-05-08),

10. 6887673 - Humanized antibodies against human 4-1BB (2005-05-03),

Title: Innovations of Subinay Ganguly in Anti-TNF Antibody Research

Introduction

Subinay Ganguly, an accomplished inventor based in Newtown, Pennsylvania, has made significant contributions to the field of biotechnology, particularly in the development of anti-TNF antibody compositions. With a portfolio consisting of ten patents, he stands out as a key figure in innovative research that has the potential to benefit therapeutic approaches for various diseases.

Latest Patents

Ganguly's latest patents focus on advanced manufacturing methods for producing anti-TNF antibody compositions. One of his notable inventions outlines a method for producing a recombinant anti-TNF antibody featuring a heavy chain comprised of amino acid sequence SEQ ID NO:36 and a light chain with amino acid sequence SEQ ID NO:37. Furthermore, he has developed methods for producing another recombinant anti-TNF antibody with a heavy chain identified as SEQ ID NO:38, again alongside the light chain SEQ ID NO:37. These innovations are pivotal for the creation of effective treatments targeting tumor necrosis factor, which plays a crucial role in inflammatory processes.

Career Highlights

Ganguly has had a fruitful career, working with prominent organizations such as Bristol-Myers Squibb Company and Janssen Biotech, Inc. His experience in these companies has provided him with a solid foundation to further his research and innovation in biotechnology.

Collaborations

Throughout his career, Ganguly has collaborated with notable coworkers, including Maria N. Jure-Kunkel and Laura J. Hefta. These partnerships have underscored his commitment to advancing the field of antibody research and enhancing the effectiveness of therapeutic applications.

Conclusion

With a strong focus on anti-TNF antibodies and a robust portfolio of patents, Subinay Ganguly continues to make remarkable strides in biotechnology. His innovations not only showcase his expertise as an inventor but also have the potential to significantly impact patient care in the medical field. As he progresses in his career, the scientific community eagerly anticipates his future contributions and developments.

This text is generated by artificial intelligence and may not be accurate.